- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Vor Biopharma files to sell 125.7M shares of common stock by selling shareholders | 2 | Seeking Alpha | ||
| 08.01. | Vor Bio expands board with new director Erez Kalir | 1 | Investing.com | ||
| 08.01. | Vor Biopharma: Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors | 2 | GlobeNewswire (USA) | ||
| 08.01. | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.01. | Eyal C. Attar Sells 10,334 Shares of Vor Biopharma Inc. (NYSE:VOR) Stock | 2 | MarketBeat | ||
| 31.12.24 | Medizinischer Leiter von Vor Biopharma verkauft Aktien im Wert von 12.917 US-Dollar | 4 | Investing.com Deutsch | ||
| 27.12.24 | Vor BioPharma stocks surge 33% after private placement | 2 | Investing.com | ||
| VOR BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.12.24 | Vor BioPharma-Aktien schießen nach Private Placement um 33% in die Höhe | 8 | Investing.com Deutsch | ||
| 27.12.24 | Vor Bio sichert sich 55,6 Millionen US-Dollar in privater Finanzierung | 3 | Investing.com Deutsch | ||
| 27.12.24 | Vor Bio secures $55.6 million in private funding | 1 | Investing.com | ||
| 27.12.24 | Vor Bio announces $55.6M private placement, shares soar | 1 | Seeking Alpha | ||
| 27.12.24 | Vor Biopharma: Vor Bio Announces $55.6 Million Private Placement | 3 | GlobeNewswire (USA) | ||
| 27.12.24 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 09.12.24 | Vor Biopharma: Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design | 111 | GlobeNewswire (Europe) | Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia (AML) patients at high risk of relapse post-transplantTrem-cel + Mylotarg continue to... ► Artikel lesen | |
| 09.12.24 | Vor Biopharma Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11.24 | Robert W. Baird Has Lowered Expectations for Vor Biopharma (NYSE:VOR) Stock Price | 1 | MarketBeat | ||
| 07.11.24 | Vor Biopharma Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09.24 | Vor Bio ernennt neuen CFO | 1 | Investing.com Deutsch | ||
| 30.09.24 | Vor Bio appoints new CFO amid clinical advancements | 4 | Investing.com | ||
| 30.09.24 | Vor Biopharma: Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer | 224 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new... ► Artikel lesen |
Seite:
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 54,81 | 0,00 % | Der neue KI-Star: Cathie Wood und Nancy Pelosi haben schon zugegriffen - Tempus AI wird zum Muss! | © Foto: Gorodenkoff / Stock.adobe.comAufgepasst Siri und Alexa! Olivia, die KI-gestützte Gesundheits-Concierge-App von Tempus AI, ist auf dem Weg. Allein ihre Ankündigung bescherte Tempus AI den besten... ► Artikel lesen | |
| DOGWOOD THERAPEUTICS | 13,160 | 0,00 % | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 | ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | Peering Into ADMA Biologics' Recent Short Interest | ||
| AVIDITY BIOSCIENCES | 30,130 | 0,00 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| IMMUNOVANT | 23,400 | 0,00 % | Immunovant, Inc. (IMVT): The Biotech Stock with Biggest Upside Potential | ||
| DYNE THERAPEUTICS | 13,690 | 0,00 % | Dyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 Therapy | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN), Tuesday announced that the U.S. Food and Drug Administration has granted Fast Track designation for DYNE-101 for the treatment of myotonic... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 49,120 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care | Advancing TP-04 (lotilaner ophthalmic gel) for the potential treatment of Ocular Rosacea, another large, underserved eye disease with no FDA-approved therapy; Initiation of Phase 2 study planned for... ► Artikel lesen | |
| DISC MEDICINE | 57,06 | 0,00 % | Disc Medicine Inc: Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission | Pursuing accelerated approval for bitopertin in EPP with protoporphyrin IX (PPIX) reduction as the surrogate endpointPlanning to submit NDA under accelerated approval pathway in H2 2025 based on existing... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,520 | 0,00 % | Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down - Should You Sell? | ||
| QIAGEN | 43,755 | -1,81 % | DAX-Check LIVE: Munich Re, Qiagen, Rheinmetall, Siemens Energy, SUSS, Zalando im Fokus | Bereits kurz nach Handelsstart markierte der DAX gestern mal wieder ein neues Allzeithoch. Und dieses hatte dann auch bis zum Ende des Tages bestand. Es liegt bei 20.675 Punkten. 20 Zähler darunter... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 5,610 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
| JANUX THERAPEUTICS | 44,620 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ONCO-INNOVATIONS | 1,970 | +36,24 % | EQS-Media: Übernahme voraus: Onco-Innovations Ltd. unterzeichnet Letter of Intent mit Inka Health Corp. | EQS-Media / 23.01.2025 / 12:12 CET/CEST
Onco-Innovations Ltd. (ISIN: CA68237C1059 / WKN: A3EKSZ) Onco oder das Unternehmen, freut sich bekannt zu geben, dass es mit Inka Health Corp., die eine... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,990 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on December 31,... ► Artikel lesen | |
| EVOTEC | 8,005 | +1,20 % | Bechtle, CompuGroup, Continental, Evotec, SMA Solar, Varta u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen |
VOR BIOPHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,530 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VOR BIOPHARMA INC finden Sie auf Wallstreet Online.
